Eli Lilly Says Retatrutide Delivers Greater Weight Loss Than Ozempic in Adults With Type 2 Diabetes

10:29 AM EDT, 10/28/2026 (MT Newswires) -- Eli Lilly (LLY) said Wednesday that data from a phase 3 head-to-head trial showed that its investigational molecule retatrutide delivered greater A1C reduction and "substantially more" weight loss than Novo Nordisk's (NVO) injectable Ozempic 2mg in adults with type 2 diabetes at 80 weeks. Lilly said the trial met the primary and all key secondary endpoints, with both 9 mg and 12 mg doses of retatrutide reducing A1C by an average of 2.2% compared with 1.8% with Ozempic 2 mg at 80 weeks. Participants taking retatrutide lost an average of 44 pounds to 47 pounds, compared with 20.9 pounds with Ozempic, Lilly said. Treatment discontinuation rates due to adverse events were 4.8% and 7.9% for retatrutide 9 mg and 12 mg, versus 2.7% with Ozempic, the company said. Novo Nordisk didn't immediately respond to a request for comment by MT Newswires. Price: 1291.24, Change: +9.33, Percent Change: +0.73